Related Experiment Video
Updated: Mar 25, 2026
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
[Network meta-analyses: Interest and limits in oncology]
Laureen Ribassin-Majed1, Jean-Pierre Pignon1, Stefan Michiels1
1Gustave-Roussy, université Paris-sud, service de biostatistiques et d'épidémiologie, 94805 Villejuif, France; Plateforme Ligue nationale contre le cancer de méta-analyse en oncologie, Gustave-Roussy, 94805 Villejuif, France.
Abstract:
In the last decade, a new method has emerged called 'network meta-analysis' to take into account all randomized trials in a given clinical setting to provide relative effectiveness between different treatments, whether or not they have been compared (pairwise) in randomized controlled trials. Network meta-analyses combine the results of direct comparisons from randomized trials with indirect comparisons between trials (i.e. when two treatments were not compared with each other, but have been studied in relation to a common comparator). The purpose of this note is to explain this method, its relevance and its limitations. A worked example in non-metastatic head and neck cancer is presented as illustration.
Insights
Network meta-analysis synthesizes all randomized trials for treatment effectiveness, even when direct comparisons are absent. This method combines direct and indirect evidence for comprehensive comparative analysis.
Area of Science:
- Clinical Epidemiology
- Biostatistics
Context:
- Randomized controlled trials (RCTs) are the gold standard for evaluating treatment efficacy.
- Limitations exist in pairwise comparisons, especially when direct trial data is scarce for all treatment combinations.
Purpose:
- To introduce and explain the methodology of network meta-analysis (NMA).
- To highlight the relevance and limitations of NMA in synthesizing evidence.
- To illustrate NMA application with a case study in non-metastatic head and neck cancer.
Summary:
- Network meta-analysis (NMA) integrates direct and indirect evidence from multiple randomized controlled trials.
- It allows for relative treatment effectiveness comparisons, even for treatments not directly compared in any single trial.
- The method leverages a common comparator to link disparate trial results.
Impact:
- Enhances evidence synthesis for complex treatment landscapes.
- Supports informed clinical decision-making by providing comprehensive comparative effectiveness data.
- Addresses limitations of traditional pairwise meta-analysis in scenarios with incomplete direct evidence.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...